Other critical site bleeding 423,0, 459.0, 568.81, 593.81, 599.7, 623.8, 626.32, 626.6, 719.1, 784.7, 784.8, 786.3 D62, J942, H113, H356, H431, N02, N95, R04, R31, R58 Discharge Figure S1 . Cumulative incidence curves of thromboembolism and bleeding for NVAF patients with liver cirrhosis according to initiated treatment before propensity score-based stabilized weights method.
The NOAC group showed a comparable risk of ischemic stroke/systemic embolism compared with warfarin group after adjustment. For the safety outcome, the NOAC group showed significantly lower risks of major gastrointestinal bleeding and all major bleeding than the warfarin group. GIB = gastrointestinal bleeding; ICH = intracranial hemorrhage; IS/SE = ischemic stroke/systemic embolism. NOAC = non-vitamin K antagonist oral anticoagulants; NVAF = non-valvular atrial fibrillation.
